glp-1/gip dual agonist mechanism of action | Tirzepatide | Obesity & T2DM Mx | Harrison's Update(22nd Ed.) Mechanisms of GLP-1 Receptor Agonist-Induced

AstraZeneca, Novo Nordisk A/S, Eli Lilly and Company, Sanofi and Hypera S.A

The messaging is about affordability and access

In clinical trials, GLP-1 RAs were shown to significantly lower blood pressure (BP) in addition to HbA1c and body weight (BW), indicating the possibility as anti-hypertensive medication of type 2 DM individuals

Here's what doctors have to say.

Use of glucagon-like peptide 1 agonists for weight loss compared with bupropion-naltrexone was associated with an increased risk for pancreatitis, gastroparesis and bowel obstruction but not biliary disease, researchers reported in JAMA

What's Included